Danning Zhao, Qin Liu^*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.084736 - 13 August 2026

Abstract Cervical cancer, particularly its advanced stages, requires novel therapeutic paradigms. Cellular immunotherapy exploits the constitutive expression of HPV E6/E7 oncoproteins as near-ideal tumor-specific antigens. This review systematically evaluates four principal platforms under investigation: tumor-infiltrating lymphocytes (TILs), TCR-engineered T cells, CAR-T cells, and CAR-NK cells. We critically analyze the preclinical rationale, clinical trial landscape, safety considerations, and manufacturing challenges for each modality. TIL therapy has achieved durable complete responses and an FDA Breakthrough Therapy designation. TCR-T cells enable precise targeting of intracellular viral epitopes but are HLA-restricted. CAR-T cells offer potent, MHC-independent recognition, yet face on-target/off-tumor More >

Abtin Tondar^1,2,*, David Hervás Marín³, Laura Calvet Liñán⁴, Asim Kumar Bepari⁵

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.082424 - 13 August 2026

Abstract Background: Chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) are B-cell malignancies with distinct cellular origins and microenvironmental dependencies. We aimed to identify concordant transcriptomic signatures and candidate transcriptional regulatory features between CLL CD19-positive B cells and MM-associated bone marrow-derived mesenchymal stromal cells (MSCs). Methods: Public Gene Expression Omnibus bulk RNA sequencing datasets were analyzed separately within each context using DESeq2. Differentially expressed genes (DEGs) were defined using adjusted p-value < 0.05 and absolute log₂ fold change > 1. Cross-disease analyses assessed overlap, directionality, log₂ fold-change concordance, expressed-gene background-adjusted enrichment, coexpression structure, and transcription factor annotation. Results: We… More >

Hsueh-Ju Lu^1,2,*, Chiao-Wen Lin^3,4, Chun-Yi Chuang^2,5, Chun-Wen Su^6,7, Shun-Fa Yang^6,7,*

Oncology Research, Vol.34, No.9, 2026, DOI:10.32604/or.2026.080527 - 13 August 2026

Abstract Background: Interleukin-31 receptor alpha (IL31RA) has been implicated in cancer progression and tumor cell migration, but its genetic associations across cancers remain unclear. This study aimed to examine IL31RA polymorphisms in relation to lymph node involvement in oral cavity squamous cell carcinoma (OCSCC). Methods: In this case-control study, 2845 participants were enrolled, including 1352 patients with OCSCC and 1493 cancer-free controls. Associations between IL31RA SNPs and OCSCC susceptibility and clinicopathological characteristics were evaluated. Functional analyses, including cell migration assays, together with bioinformatic database analyses, were performed to investigate the biological significance of IL31RA and genotype–expression correlations. Logistic… More >

Yasmine Labiad¹, Céline Baier¹, Michèle Genin², Caroline Besson^3,4, Sophie Prevot⁵, Hubert Lepidi⁶, Régis Costello^1,7,*

Oncology Research, Vol.34, No.8, 2026, DOI:10.32604/or.2026.076241 - 16 July 2026

Abstract Objectives: Transcriptomic profiling has enabled the classification of Diffuse Large B-Cell Lymphoma (DLBCL) into distinct subtypes, such as Germinal Center B-cell-like (GCB) and Activated B-cell-like (ABC), primarily in HIV-negative patients. However, HIV-associated DLBCL may follow different molecular mechanisms due to immune dysregulation. This study aimed to characterize the transcriptomic landscape of HIV-related DLBCL to identify distinct subtypes and deregulated pathways with potential theranostic implications. Methods: Twelve formalin-fixed, paraffin-embedded DLBCL samples from HIV-positive patients were analyzed using Agilent’s microarray. Quantile normalization and unsupervised hierarchical clustering were performed to classify tumors based on gene expression profiles. Results: Two distinct More > Graphic Abstract

Hsing-Ju Wu^1,2, Yu-Chieh Tsai^3,*, Hung-Yu Lin^2,4,*

European Cytokine Network, Vol.37, No.2, pp. 121-135, 2026, DOI:10.32604/ecn.2026.079012 - 30 June 2026

Abstract Backgrounds: Lymph node metastasis is a critical determinant of breast cancer prognosis, yet the specific microenvironmental cytokines driving this process remain elusive. This study aims to identify key prognostic cytokines linking nodal metastasis to tumor microenvironment (TME) remodeling and to evaluate their clinical utility. Methods: A predefined panel of 176 microenvironmental genes was evaluated using differential expression analysis and the Least Absolute Shrinkage and Selection Operator (LASSO) algorithm on the TCGA-BRCA cohort to identify optimal predictors of nodal metastasis. Prognostic value was assessed via Kaplan-Meier, subgroup, and multivariate Cox regression analyses, and validated across five… More > Graphic Abstract

Francesco Claps^1,2,*, Miguel Ramírez-Backhaus¹, Álvaro Gómez-Ferrer¹, Juan Manuel Mascarós¹, Argimiro Collado Serra¹, Augusto Wong¹, Ana Calatrava Fons³, Miguel Ángel Climent⁴, Antonio Amodeo², Angelo Porreca⁵, Jose Rubio-Briones^1,6

Canadian Journal of Urology, Vol.33, No.3, pp. 593-602, 2026, DOI:10.32604/cju.2025.070162 - 29 June 2026

Abstract Objectives: Residual Disease after adjuvant chemotherapy for non-seminomatous germ cell tumor (NSGCT) poses a significant clinical challenge and difficulties in tailored management. This study aimed to externally validate the Heidenreich criteria among patients eligible for unilateral post-chemotherapy retroperitoneal lymph node dissection (PC-RPLND) for residual masses of NSGCT. Methods: For validation, these criteria were retrospectively applied in 23 patients undergoing PC-RPLND for residual masses of NSGCTs. In patients qualified for unilateral-modified PC-RPLND according to the Heidenreich criteria but treated with fully bilateral dissection, pathological reports were evaluated to identify teratoma or active cancer cells inside the… More >

Yu-Hao Huang^1,#, Hao-Yeh Chen^2,#, Peng-Ju Chien¹, Chun-Yu Chen^2,3, Shao-Ti Li⁴, Hsueh-Te Lee⁵, Yueh-Chun Lee^4,6,*, Wen-Wei Chang^1,7,*

Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.080978 - 16 June 2026

Abstract Backgrounds: Triple-negative breast cancer (TNBC) is highly aggressive, insensitive to radiotherapy, and exhibits increased cancer stem cell (CSC) properties, contributing to poor patient outcomes. B-cell lymphoma 2 (BCL2) associated transcription factor 1 (BCLAF1) is an oncogene in certain cancers, but its role in TNBC is unclear. This study investigated BCLAF1’s involvement in radioresistance and CSC activity in TNBC. Methods: BCLAF1 expression and clinical significance were analyzed using The Cancer Genome Atlas (TCGA) breast cancer dataset. Radioresistant MDA-MB-231 cells were used to examine BCLAF1’s function. Proto-oncogene SRC (SRC) overexpression, BCLAF1 knockdown, dasatinib treatment, and hypoxia inducible factor 1 subunit… More >

Irene Bernal-Florindo^1,2, Jose Angel Raposo-Puglia^2,3, Felix A. Ruiz^2,4, Jose Perez-Requena^2,5, Cristian Benavides-de la Fuente^2,5, Javier Galan^2,6, Maria Jose Berruezo-Salazar^2,7, Marcial Garcia-Rojo^1,2, Cecilia Fernandez-Ponce^2,4,*, Antonio Santisteban-Espejo^2,8

Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.079403 - 16 June 2026

Abstract Classic Hodgkin lymphoma (CHL) constitutes a B-cell malignant lymphoid neoplasm derived from the germinal center. Despite current treatment protocols based on chemotherapy, radiotherapy, anti-cluster of differentiation (CD) 30 antibody-drug conjugates, immunotherapy, and hematopoietic stem cell transplantation (HSCT), between 10% and 20% of CHL patients fail to achieve a complete response. The reasons underlying this lack of treatment sensitivity remain unclear. Traditionally, clinical and analytical variables have constituted the cornerstone of CHL prognostic model development. However, in recent years, the distribution and spatial relationships of cancer and immune cells within the CHL tumor microenvironment (TME) have… More >

Zhihao Yin^1,2,3,#, Xi Zhen^4,#, Haonan Li^1,2,3,#, Haiqiang Duan^1,2,3,#, Xiaowei Hu^5,#, Tianxi Yu¹, Qing Shi¹, Ziyi Liu¹, Yaowei Li¹, Peng Zhang¹, Peng Dai¹, Meihui Zhao⁶, Ziqi Wang^1,2,3,7,*, Changfu Li^2,*, Di Wang^1,*, Zhichao Tong^1,3,5,8,9,*

Oncology Research, Vol.34, No.7, 2026, DOI:10.32604/or.2026.077808 - 16 June 2026

Abstract Backgrounds: Tertiary lymphoid structures (TLSs) are increasingly recognized as modulators of anti-tumor immunity, yet their clinical relevance in bladder cancer remains incompletely understood, partly owing to heterogeneity in their maturation states. Here, we demonstrate that germinal center (GC)–like TLS maturity, rather than TLS presence alone, is closely associated with immune activation and therapeutic response to Programmed Death-Ligand 1 (PD-L1) blockade in bladder cancer. The objective of this study was to systematically investigate the clinical significance, biological function, and therapeutic potential of tertiary lymphoid structure (TLS) maturation in bladder cancer. Specifically, we aimed to determine whether GC-like… More >

Christoph Rehbach¹, Patrick A. H. Ehm^2,*

BIOCELL, Vol.50, No.5, 2026, DOI:10.32604/biocell.2026.075170 - 13 May 2026

Abstract Despite improved overall prognosis, the treatment of high-risk acute lymphoblastic leukemia (ALL) remains challenging due to the toxicity of intensive polychemotherapy and the limited efficacy of antibody-targeted therapies beyond cluster of differentiation 20 and 22 (CD20 and CD22). ALL is driven not only by genetic alterations but also by profound epigenetic dysregulation, including promoter hypermethylation that also silences surface receptor genes. This epigenetic repression can reduce the efficacy of targeted immunotherapies and contribute to relapse. Epigenetic reprogramming with DNA demethylating agents (e.g., decitabine) has the potential to restore the expression of key B cell receptors… More >